Luteinizing Hormone-Releasing Hormone Analog

DRUG3 trials

Sponsors

University of Sydney, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, Zhujiang Hospital

Conditions

AbirateroneOligometastatic Prostate CancerProstate CancerProstate Cancer With ≤10 Bone MetastasesProstatectomy

Phase 2

The Efficacy and Safety of Prostatectomy for Castration-Naive Oligometastatic Prostate Cancer

CompletedNCT04992026

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolAbiraterone, Oligometastatic Prostate Cancer, Prostatectomy

Start: 2021-01-01End: 2024-12-02Updated: 2024-12-05

Phase 3

Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate

Active, not recruitingNCT04136353

University of SydneyProstate Cancer

Start: 2020-03-31End: 2028-07-31Updated: 2023-07-28

Unknown Phase

Efficacy and Safety of Apalutamide in Combination With 89Sr as Neoadjuvant Therapy in Prostate Cancer With ≤10 Bone Metastases

RecruitingNCT05740488

Zhujiang HospitalProstate Cancer With ≤10 Bone Metastases

Start: 2022-01-07End: 2025-12-31Target: 30Updated: 2024-03-15

Related Papers

Baseline disease characteristics of participants enrolled on ENZARAD (ANZUP1303) and DASL-HiCaP (ANZUP1801) trials of highly effective androgen receptor antagonists in high-risk localized or locally advanced prostate cancer (PCa).

Journal of Clinical Oncology2024-01-292 citations

DASL-HiCaP: A randomized, phase 3, double-blind trial of darolutamide with androgen-deprivation therapy and definitive or salvage radiation for localized very high-risk prostate cancer.

Journal of Clinical Oncology2023-02-201 citations

A retrospective study to evaluate the effect of preoperative hormonal therapy on continence recovery

Frontiers in Oncology2023-01-13

DASL-HiCaP: Darolutamide augments standard therapy for localized very high-risk cancer of the prostate (ANZUP1801)—A randomized phase 3, double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation.

Journal of Clinical Oncology2022-06-012 citations

DASL-HiCaP: Darolutamide augments standard therapy for localized very high-risk cancer of the prostate (ANZUP1801). a randomized phase 3 double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation.

Journal of Clinical Oncology2022-02-161 citations

DASL-HiCaP: Darolutamide augments standard therapy for localized very high-risk cancer of the prostate (ANZUP1801)—A randomized phase III double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation.

Journal of Clinical Oncology2021-02-20

DASL-HiCAP (ANZUP1801): The impact of darolutamide on standard therapy for localized very high-risk cancer of the prostate—A randomized phase III double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation in very high-risk, clinically localized prostate cancer.

Journal of Clinical Oncology2020-02-192 citations